Cogent Biosciences develops bezuclastinib, an oral, highly selective KIT inhibitor that targets activation‑loop mutations such as KIT D816V while sparing off‑target kinases. The drug is being evaluated in registration‑directed trials for systemic mastocytosis and imatinib‑resistant gastrointestinal stromal tumors, offering mutation‑specific therapy with reduced class‑related toxicities. Its design also supports combination with sunitinib to address resistance.
Funding
$230M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with genetically defined diseases such as systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST) often face limited therapeutic options. Existing tyrosine‑kinase inhibitors either lack activity against key KIT activation‑loop mutations (e.g., KIT D816V) or cause dose‑limiting off‑target toxicities, leaving a substantial unmet need for safe, mutation‑specific treatments.
Solution
Cogent Biosciences applies a precision‑medicine platform that leverages validated disease biology to design rational small‑molecule therapeutics. Its lead candidate, bezuclastinib, is a highly selective, potent KIT inhibitor engineered to block activation‑loop mutations while sparing related kinases, thereby reducing off‑target adverse effects. The drug is being evaluated in registration‑directed clinical programs—including APEX for advanced SM, SUMMIT for non‑advanced SM, and PEAK (bezuclastinib + sunitinib) for imatinib‑resistant GIST—demonstrating clinically meaningful responses in recent top‑line data. By focusing on genetically driven disease mechanisms, Cogent aims to deliver durable disease control and improved quality of life for patients lacking effective options today.
Target Audience
Primary customers are oncologists, hematologists, and clinical researchers treating patients with systemic mastocytosis or gastrointestinal stromal tumors who require mutation‑specific, low‑toxicity therapies.
Features
- Small‑molecule tyrosine‑kinase inhibitor (TKI) with nanomolar potency against KIT exon 17 mutations, including KIT D816V.
- High selectivity profile: minimal activity on off‑target kinases, reducing class‑related toxicities such as edema, hypertension, and pleural effusion.
- Oral formulation suitable for chronic administration in both hematologic (SM) and solid‑tumor (GIST) indications.
- Combination‑ready design enabling co‑administration with sunitinib to address primary and secondary KIT resistance mutations in GIST.
- Comprehensive clinical development pipeline: Phase 2 APEX (advanced SM), Phase 2 SUMMIT (non‑advanced SM), Phase 3 PEAK (GIST) with ongoing expanded‑access programs.
- Biomarker‑driven patient selection strategy using KIT mutation profiling to match therapy to the underlying genetic driver.
- Integrated data platform for real‑time safety monitoring and efficacy readouts across multi‑center trials.